Roger Song Analyst PerformanceBiotech Equity Research at Jefferies Financial GroupRoger Song is a stock analyst at Jefferies Financial Group in the healthcare sector, covering 27 publicly traded companies. Over the past year, Roger Song has issued 30 stock ratings, including buy and hold recommendations. While full access to Roger Song's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Roger Song's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings43 Last 5 YearsBuy Recommendations90.70% 39 Buy RatingsCompanies Covered27 Unique Companies Ratings Distribution43RatingsDistribution of strong buy, buy, hold, and sell ratings by Roger Song.RatingPercentageCount Strong Buy0.0%0 ratings Buy90.7%39 ratings Hold9.3%4 ratings Sell0.0%0 ratingsOut of 43 total stock ratings issued by Roger Song at Jefferies Financial Group, the majority (90.7%) have been Buy recommendations, followed by 9.3% Hold.Best & Worst CallsBest Call0000.0%NKTRApr 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%NVAXFeb 2022Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ96.3% of companies on NASDAQ26 companiesNYSE3.7% of companies on NYSE1 companyRoger Song, an analyst at Jefferies Financial Group, currently covers 27 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare27 companies100.0%Roger Song of Jefferies Financial Group specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY24 companies88.9%PHARMACEUTICALS3 companies11.1% Roger Song's Ratings History at Jefferies Financial Group Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsINOInovio Pharmaceuticals8/13/2026Upgrade$0.77$3.00Positive$0.0000.00% ROIMANEVeradermics7/7/2026Boost Price Target$119.47$182.00Buy$0.0000.00% ROINRIXNurix Therapeutics6/8/2026Boost Price Target$15.59$45.00Buy$0.0000.00% ROISABSSAB Biotherapeutics5/20/2026Initiated Coverage$3.55$11.00Buy$0.0000.00% ROISABSSAB Biotherapeutics5/20/2026Initiated Coverage$3.68$11.00Buy$0.0000.00% ROIKLRAKailera Therapeutics5/12/2026Initiated Coverage$22.93$48.00Buy$0.0000.00% ROIKLRAKailera Therapeutics5/12/2026Initiated Coverage$22.30$48.00Buy$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International4/28/2026Boost Price Target$53.40$71.00Buy$0.0000.00% ROIREPLReplimune Group4/13/2026Reiterated Rating$4.77$2.00Hold$0.0000.00% ROIALLOAllogene Therapeutics4/13/2026Boost Price Target$2.28$10.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. ALLOAllogene Therapeutics4/10/2026Initiated Coverage$2.67$6.00Buy$0.0000.00% ROIPTGXProtagonist Therapeutics3/18/2026Reiterated Rating$98.30$121.00Buy$0.0000.00% ROICTMXCytomX Therapeutics3/18/2026Boost Price Target$4.73$16.00Buy$0.0000.00% ROIMANEVeradermics3/2/2026Initiated Coverage$45.70$75.00Buy$0.0000.00% ROIMANEVeradermics3/2/2026Initiated Coverage$46.54$75.00Buy$0.0000.00% ROIKRYSKrystal Biotech2/17/2026Boost Price Target$295.25$371.00Buy$0.0000.00% ROIPTGXProtagonist Therapeutics2/2/2026Boost Price Target$83.05$118.00Buy$0.0000.00% ROICRVSCorvus Pharmaceuticals1/22/2026Boost Price Target$25.92$42.00Buy$0.0000.00% ROIZBIOZenas BioPharma1/6/2026Reiterated Rating$16.61$48.00Buy$0.0000.00% ROINKTRNektar Therapeutics12/17/2025Reiterated Rating$49.16Buy$0.0000.00% ROINKTRNektar Therapeutics11/24/2025Reiterated Rating$54.28$121.00Buy$0.0000.00% ROIUTHRUnited Therapeutics11/19/2025Reiterated Rating$476.59$575.00Buy$0.0000.00% ROIORKAOruka Therapeutics11/13/2025Initiated Coverage$28.30$45.00Buy$0.0000.00% ROIUTHRUnited Therapeutics10/29/2025Reiterated Rating$455.32Buy$0.0000.00% ROIZBIOZenas BioPharma10/27/2025Reiterated Rating$31.98$52.00Buy$0.0000.00% ROIGYREGyre Therapeutics10/10/2025Initiated Coverage$7.15$16.00Buy$0.0000.00% ROIGYREGyre Therapeutics10/10/2025Initiated Coverage$8.01$16.00Buy$0.0000.00% ROITRMLTourmaline Bio9/9/2025Downgrade$47.64$47.50Hold$0.0000.00% ROIBMEABiomea Fusion8/28/2025Initiated Coverage$1.86$5.00Buy$0.0000.00% ROIBMEABiomea Fusion8/28/2025Initiated Coverage$1.92$5.00Buy$0.0000.00% ROIATYRaTyr Pharma8/22/2025Boost Price Target$5.33$17.00Buy$0.0000.00% ROILVTXLAVA Therapeutics8/5/2025Downgrade$1.47$1.50Hold$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International7/29/2025Boost Price Target$30.37$54.00Buy$00.0000.00% ROIREPLReplimune Group7/22/2025Lower Price Target$2.92$6.00Buy$00.0000.00% ROICVACCureVac6/13/2025Reiterated Rating$5.60$5.00Hold$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International4/29/2025Boost Price Target$25.88$45.00Buy$00.0000.00% ROINKTRNektar Therapeutics4/11/2025Upgrade$7.49$30.00Buy$00.0000.00% ROIAKBAAkebia Therapeutics4/1/2025Initiated Coverage$1.92$6.00Buy$0.0000.00% ROISANASana Biotechnology3/14/2025Initiated Coverage$2.65$7.00Buy$0.0000.00% ROIKRYSKrystal Biotech3/5/2025Initiated Coverage$175.22$245.00Buy$000.0000.00% ROIA letter from Shannon Stansberry (Ad)Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.Watch the full story and see the verified track record for yourselfWVEWAVE Life Sciences2/25/2025Initiated Coverage$10.48$26.00Buy$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenWeiss RatingsCitigroupUBS GroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank Aktiengesellschaft Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
